The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.
Frequently asked questions
What is the ProShares Ultra Nasdaq Biotechnology (BIB) expense ratio?
The ProShares Ultra Nasdaq Biotechnology funds expense ratio is 0.95%.
What is ProShares Ultra Nasdaq Biotechnology (BIB) current stock price?
As of the latest data, ProShares Ultra Nasdaq Biotechnology stock price is $111.99, with a previous close of $109.64. ProShares Ultra Nasdaq Biotechnology gained $2.35 in the last trading session, representing a 2.14% increase.
Does ProShares Ultra Nasdaq Biotechnology (BIB) pay dividends?
Yes. ProShares Ultra Nasdaq Biotechnology pays quarterly dividends with an annualized yield of 0.03% and an estimated annual payout of $0.03 per share.
When is the next ex-dividend date for ProShares Ultra Nasdaq Biotechnology (BIB)?
The next ex-dividend date is scheduled for September 24, 2026.